|
WO2019193062A1
|
|
Substituted pyrrolidines and their use
|
|
TW201831471A
|
|
Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
|
|
EP3558982A1
|
|
Deuterated cftr modulators and methods of use
|
|
WO2018073175A1
|
|
Compounds and pharmaceutical compositions thereof for use in the treatment of cystic fibrosis
|
|
US2018099931A1
|
|
Substituted pyrrolidines and methods of use
|
|
US2018099932A1
|
|
Substituted pyrrolidines and methods of use
|
|
US2017349576A1
|
|
Heteroaryl substituted pyridines and methods of use
|
|
CA3016303A1
|
|
Modulators of cystic fibrosis transmembrane conductance regulator protein
|
|
EP3359144A1
|
|
Potentiator-corrector combinations useful in the treatment of cystic fibrosis
|
|
MX2018004359A
|
|
N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use.
|
|
BR112018007145A2
|
|
substituted pyrazolo [3,4-b] pyridin-6-carboxylic acids and their use
|
|
BR112018007165A2
|
|
new compounds for cystic fibrosis treatment
|
|
MX2018000688A
|
|
Substituted tricyclics and method of use.
|
|
CA2988046A1
|
|
Substituted pyridines and method of use
|
|
AU2015339196A1
|
|
Substituted tetrahydropyrans and method of use
|
